Journal Information
Vol. 97. Issue 6.
Pages 704-709 (01 November 2022)
Visits
...
Vol. 97. Issue 6.
Pages 704-709 (01 November 2022)
Original Article
Open Access
A low level of health literacy is a predictor of corticophobia in atopic dermatitis
Visits
...
Tiago Fernandes Gomes
Corresponding author
tiagofgomesd@gmail.com

Corresponding author.
, Katarina Kieselova, Victoria Guiote, Martinha Henrique, Felicidade Santiago
Department of Dermatology, Centro Hospitalar de Leiria, Leiria, Portugal
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Abstract
Background

Topical corticosteroids (TCS) are the mainstay of treatment in atopic dermatitis (AD) flares. The fears and worries concerning TCS are known as corticophobia. Corticophobia is common in patients with AD and can lead to suboptimal TCS application and treatment failure. Health literacy (HL) may influence corticophobia. TOPICOP© and HLS-EU-PT questionnaires have been developed to evaluate corticophobia and HL, respectively.

Objective

Evaluate the relationship between corticophobia and the degree of HL in patients with AD.

Methods

Prospective cross-sectional study with AD patients followed at a Dermatology Department, between September 2019 and February 2020. Patients, or their parents (if patients had ≤ 15 years), were invited to answer TOPICOP© questionnaire, HLS-EU-PT questionnaire, and a disease characterization and demographic questionnaire.

Results

We included 61 patients (57.4% females, mean age 20 ± 13.8 years, mean disease duration of 12.5 ± 11.4 years). TOPICOP© mean score was 44.8 ± 20.0 (8.3 to 88.9) and HLS-EU-PT mean score was 30.5 ± 8.5 (1.1 to 47.9). TOPICOP© score was negatively correlated with HLS-EU-PT score (p = 0.002, r = -0.382,  r2 = 0.146). There was no statistical difference between TOPICOP© score and disease characteristics (disease severity, family history of AD or personal history of other atopic diseases).

Study limitations

Small and heterogenous cohort composed of patients and patients’ parents.

Conclusion

The degree of corticophobia is similar to the values reported in other studies. HL had an inverse correlation with corticophobia. Lower HL was shown to be a predictor of higher corticophobia. The promotion of health literacy is essential for the correct use of TCS and good control of AD.

Keywords:
Dermatitis
Atopic
Health literacy
Steroids
Therapeutics
Full Text
Introduction

Atopic dermatitis (AD) is a chronic relapsing inflammatory skin disorder with a significant impact on the quality of life.1 Globally, its prevalence is increasing, affecting up to 20% of children and 10% of adults.2–5 Topical anti-inflammatory therapies are the first step of treatment in AD flares.6,7 Topical corticosteroids (TCS) are the mainstay of treatment in most patients with AD and they often require long-term treatment with TCS for many years. Poor adherence to treatment is common in AD and can lead to treatment failure.8–10 TCS resistance may be partially due to non-adherence because of TCS phobia.11 TCS phobia, also known as corticophobia, defines the negative feelings and beliefs related to TCS experienced by patients and their caregivers. The prevalence of corticophobia in AD ranges from 21% to 84%.12 Health literacy is the term used to describe people's capacities to meet the complex demands related to health in modern society. It results from health education and communication activities and determines the individual ability to gain access to, understand, and use information in order to promote and maintain good health.13,14 The present group of authors proposed to study the effect of health literacy on corticophobia.

MethodsPatients and setting

We conducted a prospective cross-sectional study at the Department of Dermatology of a level 2 Hospital in Portugal, between September 2019 and February 2020. Patients with atopic dermatitis, with at least 2 Dermatology appointments were included. We defined two groups according to the age of the patient: ≤ 15 years and > 15 years.

Questionnaires

Parents of the patients with ≤ 15 years and the patients with >15 years were invited to answer three questionnaires: TOPICOP© questionnaire, HLS-EU-PT questionnaire, and a disease characterization and demographic questionnaire.

TOPICOP© is a validated scale for the assessment of TCS phobia among AD patients and their parents.15 The feasibility and comprehensibility of the TOPICOP© score have been addressed across different countries.16 The original version is in the English language, but Portuguese and foreign languages are available at http://www.edudermatologie.com. It comprises 12 items, covering “worries” (6 items) and “beliefs” (6 items). Four response choices are offered, from totally disagree to totally agree, with points attributed to each one (0, 1, 2 or 3).15

European health literacy survey (HLS-EU) questionnaire is a validated tool for measuring the health literacy (HL) of the general population, also validated in the Portuguese language (HLS-EU-PT).14,17 HLS-EU-PT includes 47 questions, which integrate three different health domains: healthcare, disease prevention, and health promotion.14,18 For each item, patients rate the perceived difficulty of a given task on a four-category Likert scale (very easy, easy, difficult, and very difficult).18

A third questionnaire was applied to provide additional clinical data. This included demographic information such as gender, age, working in a healthcare setting, and disease characteristics such as duration of disease, family history of AD, personal history of asthma and/or allergic rhinitis, and previous AD treatments.

Statistical analysis

TOPICOP© score was calculated as 100% times the sum of all responses divided by the maximum possible sum for the included questions, with a resulting score of 0 to 100% of TCS phobia.15 The score can be further categorized in low (≤ 23), intermediate (24‒50), and high (> 50).19 For HLS-EU-PT, a mean-based item score was calculated for each patient with a least 80% responses. The index score was transformed in a unified metric from 0 to 50 using the following formula: (mean–1)×50 ÷ 3. The final score is inserted in one of four levels of HL: “inadequate” (0‒25), “problematic” (> 25‒33), “sufficient” (> 33‒42), and “excellent” (> 42‒50).18 Results are expressed as percentages or means ± standard deviation, and statistical analyses were performed using SPSS version 22 (SPSS Inc., IBM-SPSS, Chicago, IL). Variables were tested for normality with the Kolmogorov-Smirnov test. For the univariate analysis, relationships between TOPICOP© score and covariate were evaluated using Pearson’s correlation test. When necessary, Student’s t-test was used. Pearson correlation and univariate linear regression tests were used to measure the effect of health literacy (provided by HLS-EU-PT score) on TCS phobia (measured by TOPICOP©).

Missing data were not replaced. Statistical significance was set at p < 0.05.

Ethics

This study was approved by the Hospital Medical Ethical Research Committee. Measures were taken to maintain the privacy of the patients, by processing anonymously the questionnaires.

Results

Patient characteristics are listed in Table 1. A total of 61 patients were included, 35 (57.4%) females, with a mean age of 20 ± 13.8 years. We had 25 patients (41.0%) with ≤ 15 years and 36 (59.0%) with > 15 years. Ten (16.4%) of the responders worked on a healthcare setting. The mean duration of AD was 12.5 ± 11.4 years. Other atopic diseases (asthma and/or allergic rhinitis) were present in 35 patients (57.4%) and 31 (50.8%) had a family history of AD. Most of the patients had mild disease (38 patients, 62.3%). Fifty-nine patients (96.7%) confirmed treatment with TCS. Other treatments used for AD are described in Table 1.

Table 1.

Population characterization.

Population characterization  n (%)  Mean ± SD (min–max) 
Age, years    20.0 ± 13.8 (1–49)
≤15 years  25 (41.0) 
>15 years  36 (59.0) 
Gender   
Female  35 (57.4) 
Male  26 (42.6) 
Duration of the disease, years    12.5 ± 11.4 (0–47.0) 
Healthcare professional   
Yes  10 (16.4) 
No  51 (83.6) 
Family history of AD   
Yes  31 (50.8) 
No  30 (49.2) 
Personal history of asthma and/or allergic rhinitis   
Yes  35 (57.4) 
No  26 (42.6) 
Severity of AD   
Mild  38 (62.3) 
Moderate to severe  23 (37.7) 
Current and/or previous treatments   
Moisturizer  59 (96.7) 
Topical corticosteroid  59 (96.7) 
Topical calcineurin inhibitor  21 (34.4) 
Systemic corticosteroids  16 (26.2) 
Cyclosporine  14 (23.0) 
Methotrexate  6 (9.8) 
Phototherapy  5 (8.2) 
Dupilumab  2 (3.3) 
TOPICOP©    44.8 ± 20.0 (8.3–88.9) 
Low (n, %)  9 (14.8) 
Moderate (n, %)  31 (50.8) 
High (n, %)  21 (34.4) 
Mean HLS-EU-PT    30.5 ± 8.5 (1.1–47.9)
Inadequate (n, %)  13 (21.3) 
Problematic (n, %)  26 (42.6) 
Sufficient (n, %)  16 (26.2) 
Excellent (n, %)  6 (9.8) 

TOPICOP© levels ranged from 8.3 to 88.9, with a mean score of 44.8 ± 20.0, which indicates a moderate level of TCS phobia. Nine patients (14.8%) had a low TOPICOP© score, 31 (50.8%) had an intermediate score and 21 (34.4%) had a high score.

HLS-EU-PT scores ranged from 1.1 to 47.9, with a mean score of 30.5 ± 8.5, considered a level of problematic HL. Inadequate HL was present in 13 (21.3%), problematic HL in 26 (42.6%), sufficient in 16 (26.2%) and excellent in 6 (9.8%).

No statistically significant difference was found for TOPICOP© score between the caregivers’ responders (patients with ≤ 15 years) and patients’ responders (> 15 years) (p = 0.189). Similarly, no statistically significant difference was found for TOPICOP© scores between healthcare professionals and other occupations, family history of AD, personal history of other atopic diseases, and disease severity (Table 2). TOPICOP© value was shown to be negatively correlated with HLS-EU-PT value (p = 0.002, r = -0.382,  r2 = 0.146), with higher levels of TOPICOP© associated with lower HLS-EU-PT value (Table 3).

Table 2.

TOPICOP© variation between groups.

Variables  TOPICOP (mean ± SD)  p-value 
Age     
≤15 years  40.8 ± 20.8  0.189 
>15 years  47.6 ± 19.1   
Healthcare professional     
Yes  34.5 ± 15.3  0.073 
No  46.9 ± 20.2   
Family history of AD     
Yes  46.2 ± 22.4  0.583 
No  43.4 ± 17.2   
Personal history of asthma and/or allergic rhinitis     
Yes  42.9 ± 20.8  0.379 
No  47.5 ± 18.8   
Severity of the disease     
Mild  41.6 ± 19.2  0.099 
Moderate to Severe  50.2 ± 20.3   
Table 3.

Pearson correlation of TOPICOP© with HLS-EU-PT.

Correlations  R2  p-value 
TOPICOP© – HLS-EU-PT  -0.382  0.146  0.002 
Discussion

TCS is the first-line anti-inflammatory treatment for AD.6 Corticophobia may impair an adequate treatment regimen, leading to an uncontrolled disease with a negative impact on the quality of life. The right amount of TCS to use and frequency of applications are some of the concerns that should be addressed with these patients.20 The fear of TCS side effects may be a major concern in AD patients and their caregivers and is frequently implicated in TCS resistance.9,20,21 Cutaneous atrophy, purpura, telangiectasias, striae, perioral dermatitis, or acne are some of the adverse events that may occur with prolonged and inadequate administration of TCS.22 The increased percutaneous absorption may be responsible for systemic adverse effects, such as hypothalamic-pituitary-adrenal axis suppression and glaucoma, but the risk seems to be low.23,24 In general, TCS long-term treatments are considered safe in both adults and children.23,25–27

Nowadays, there is accessible access to the medical information in the media, such as newspapers, magazines, and the internet. However, much of this information is not produced by healthcare professionals and may erroneously induce the patient to undertreat with TCS. In fact, a Korean study showed that the internet (49.2%), television or other broadcasting media (45.2%), doctors/healthcare professionals (37.3%), and magazines/newspapers were sources of information associated with steroid phobia.28 Patients may have difficulties in selecting correct and trustworthy medical information.

TOPICOP© is currently the only validated score to assess TCS phobia. 16 In the present study, TOPICOP© questionnaire showed an average level of 44.8% in our population, which indicates an intermediate level of TCS phobia. Other groups reported similar levels of corticophobia levels.16,19,29 Stalder et al. reported a mean global TOPICOP© score of 44.7% in a prospective multicenter study conducted with 1796 participants from 17 countries.16 In a smaller study, Bos et al. found a TOPICOP© score of 44% in a group of 29 parents of patients with AD from the Netherlands.29 A French study by Dufresne et al. with 191 parents found a TOPICOP© score of 39.8%, slightly lower than the other studies, but these parents attended a therapeutic education program, which may have been responsible for the better results.19

In the present study, the authors’ main goal was to evaluate the association between TCS phobia and health literacy. The general HL index reported for Portugal was 33.0, and 11% of the Portuguese population had an “inadequate” HL score, and 38% had a “problematic” score.30 In the present study, we had a mean HLS-EU-PT of 30.5 ± 8.5 and 63.9% had lower levels (“inadequate” and “problematic”). Interestingly, we found a significant negative correlation between TOPICOP© score and HLS-EU-PT. Furthermore, lower HL was a predictor of higher corticophobia. This emphasizes the importance of HL in healthcare. The present results contrast with the findings of Dufresne et al., in which the literacy score was significantly associated with higher TCS phobia.19 Most of the corticophobic parents of their study had direct access to scientific and online resources and a higher TOPICOP© score was associated with completed years after graduation. However, these authors had a more homogenous group, including only parents of AD children (<18 years). The inclusion of a group of parents of younger patients and a group of older patients may be a limitation of the present study since it makes a more heterogenous cohort and may impact the general group analysis. Another limitation was the small number of patients in each group. Future studies with larger and more homogenous cohorts should be done in order to confirm the present findings.

Physicians should develop teaching techniques in order to properly educate their patients about the disease and the recommended treatment.11 However, TCS phobia is also present among healthcare professionals, and it may affect patients (or their caregivers) perspectives of TCS use and adherence.29,31 Education of these professionals may improve patients' adherence to treatment. It was shown that having trust toward a physician is significantly associated with taking medication as directed.9 Education of pharmacy staff to provide patient counseling was also shown to be effective in reducing TCS phobia.32 Doctors should provide detailed written instructions on TCS regimens and answer any concerns that patients and caregivers may have.

The promotion of HL should be a priority in public health. The improvement of individual and social critical skills regarding their health will maximize the engagement of healthy behaviors.

Conclusion

Corticophobia is an impediment towards an appropriate therapeutic regimen in cutaneous conditions such as AD. The easy accessibility to information on TCS and their side effects may paradoxically contribute to the fear and worries about them. Patients need to be capable of selecting and filtering reliable content. HL is responsible for the capacity and critical choice in health behaviors. The present study suggests that higher HL is associated with lower TCS phobia, but more studies are needed to clarify this association. To the authors’ knowledge, this study provides the first evaluation of TCS phobia in Portugal.

Financial support

None declared.

Authors’ contributions

Tiago Fernandes Gomes: Effective participation in research orientation; data collection, analysis, and interpretation; statistical analysis; critical literature review; preparation and writing of the manuscript.

Katarina Kieselova: Approval of the final version of the manuscript; data collection, analysis, and interpretation; manuscript critical review.

Victoria Guiote: Approval of the final version of the manuscript; data collection, analysis, and interpretation; effective participation in research orientation; manuscript critical review.

Martinha Henrique: Approval of the final version of the manuscript; data collection, analysis, and interpretation; manuscript critical review.

Felicidade Santiago: Study conception and planning; approval of the final version of the manuscript; data collection, analysis, and interpretation; statistical analysis; intellectual participation in propaedeutic and/or therapeutic management of studied cases; manuscript critical review.

Conflict of interest

None declared.

References
[1]
T. Torres, E.O. Ferreira, M. Gonçalo, P. Mendes-Bastos, M. Selores, P. Filipe.
Update on Atopic Dermatitis.
Acta Med Port, 32 (2019), pp. 606-613
[2]
Z.C.C. Fuxench, J.K. Block, M. Boguniewicz, J. Boyle, L. Fonacier, J.M. Gelfand, et al.
Atopic Dermatitis in America Study: A Cross-Sectional Study Examining the Prevalence and Disease Burden of Atopic Dermatitis in the US Adult Population.
J Invest Dermatol, 139 (2019), pp. 583-590
[3]
R. Sacotte, J.I. Silverberg.
Epidemiology of adult atopic dermatitis.
Clin Dermatol, 36 (2018), pp. 595-605
[4]
J.I. Silverberg, J.M. Hanifin.
Adult eczema prevalence and associations with asthma and other health and demographic factors: A US population-based study.
J Allergy Clin Immunol, 132 (2013), pp. 1132-1138
[5]
J.A. Odhiambo, H.C. Williams, T.O. Clayton, C.F. Robertson, M.I. Asher.
Global variations in prevalence of eczema symptoms in children from ISAAC Phase Three.
J Allergy Clin Immunol, 124 (2009), pp. 1251-1258.e23
[6]
A. Wollenberg, S. Barbarot, T. Bieber, S. Christen-Zaech, M. Deleuran, A. Fink-Wagner, et al.
Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I.
J Eur Acad Dermatology Venereol, 32 (2018), pp. 657-682
[7]
S.M. Langan, A.D. Irvine, S. Weidinger.
Atopic dermatitis.
[8]
A. Sokolova, S.D. Smith.
Factors contributing to poor treatment outcomes in childhood atopic dermatitis.
Australas J Dermatol, 56 (2015), pp. 252-257
[9]
K. Capozza, A. Schwartz.
Does it work and is it safe? Parents’ perspectives on adherence to medication for atopic dermatitis.
Pediatr Dermatol, 37 (2020), pp. 58-61
[10]
M. El Hachem, F. Gesualdo, G. Ricci, A. Diociaiuti, L. Giraldi, O. Ametrano, et al.
Topical corticosteroid phobia in parents of pediatric patients with atopic dermatitis: a multicentre survey.
Ital J Pediatr, 43 (2017), pp. 22
[11]
L. Eicher, M. Knop, N. Aszodi, S. Senner, L.E. French, A. Wollenberg.
A systematic review of factors influencing treatment adherence in chronic inflammatory skin disease – strategies for optimizing treatment outcome.
J Eur Acad Dermatology Venereol, 33 (2019), pp. 2253-2263
[12]
A.W. Li, E.S. Yin, R.J. Antaya.
Topical Corticosteroid Phobia in Atopic Dermatitis.
JAMA Dermatology, 153 (2017), pp. 1036-1042
[13]
K. Sørensen, S. Van den Broucke, J. Fullam, G. Doyle, J. Pelikan, Z. Slonska, et al.
Health literacy and public health: A systematic review and integration of definitions and models.
BMC Public Health, 12 (2012), pp. 80
[14]
K. Sørensen, S. Van den Broucke, J.M. Pelikan, J. Fullam, G. Doyle, Z. Slonska, et al.
Measuring health literacy in populations: illuminating the design and development process of the European Health Literacy Survey Questionnaire (HLS-EU-Q).
BMC Public Health, 13 (2013), pp. 948
[15]
L. Moret, E. Anthoine, H. Aubert-Wastiaux, A. Le Rhun, C. Leux, J. Mazereeuw-Hautier, et al.
TOPICOP©: A New Scale Evaluating Topical Corticosteroid Phobia among Atopic Dermatitis Outpatients and Their Parents. Szecsi PB, editor.
[16]
J.-F. Stalder, H. Aubert, E. Anthoine, M. Futamura, D. Marcoux, M.-A. Morren, et al.
Topical corticosteroid phobia in atopic dermatitis: International feasibility study of the TOPICOP score.
Allergy, 72 (2017), pp. 1713-1719
[17]
A.R. Pedro.
Literacia em Saúde: da gestão da informação à decisão inteligente. Lisboa.
Tese [Doutorado em Saúde Pública] ‒ Escola Nacional de Saúde Pública, Universidade Nova de Lisboa, (2018),
[18]
K. Sørensen, J.M. Pelikan, F. Röthlin, K. Ganahl, Z. Slonska, G. Doyle, et al.
Health literacy in Europe: comparative results of the European health literacy survey (HLS-EU).
Eur J Public Health, 25 (2015), pp. 1053-1058
[19]
H. Dufresne, P. Bataille, N. Bellon, S. Compain, E. Deladrière, L. Bekel, et al.
Risk factors for corticophobia in atopic dermatitis.
J Eur Acad Dermatology Venereol, 34 (2020), pp. 846-849
[20]
H. Aubert-Wastiaux, L. Moret, A. Le Rhun, A.M. Fontenoy, J.M. Nguyen, C. Leux, et al.
Topical corticosteroid phobia in atopic dermatitis: a study of its nature, origins and frequency.
Br J Dermatol, 165 (2011), pp. 808-814
[21]
C.R. Charman, A.D. Morris, H.C. Williams.
Topical corticosteroid phobia in patients with atopic eczema.
Br J Dermatol, 142 (2000), pp. 931-936
[22]
U.R. Hengge, T. Ruzicka, R.A. Schwartz, M.J. Cork.
Adverse effects of topical glucocorticosteroids.
J Am Acad Dermatol, 54 (2006), pp. 1-15
[23]
E.C. Siegfried, J.C. Jaworski, J.D. Kaiser, A.A. Hebert.
Systematic review of published trials: long-term safety of topical corticosteroids and topical calcineurin inhibitors in pediatric patients with atopic dermatitis.
BMC Pediatr, 16 (2016), pp. 75
[24]
L. Eichenfield, C.N. Ellis, D. Fivenson, A.A. Hebert, S. Dromgoole, D. Piacquadio.
Evaluation of Adrenal Suppression of a Lipid Enhanced, Topical Emollient Cream Formulation of Hydrocortisone Butyrate 0.1% in Treating Children with Atopic Dermatitis.
Pediatr Dermatol, 24 (2007), pp. 81-84
[25]
J. Faergemann, O. Christensen, P. Sjovall, A. Johnsson, K. Hersle, P. Nordin, et al.
An open study of efficacy and safety of long-term treatment with mometasone furoate fatty cream in the treatment of adult patients with atopic dermatitis.
J Eur Acad Dermatology Venereol, 14 (2000), pp. 393-396
[26]
M.-H. Tan, S.L. Meador, G. Singer, M.G. Lebwohl.
An open-label study of the safety and efficacy of limited application of fluticasone propionate ointment, 0.005%, in patients with atopic dermatitis of the face and intertriginous areas.
Int J Dermatol, 41 (2002), pp. 804-809
[27]
U. Blume-Peytavi, U. Wahn.
Optimizing the treatment of atopic dermatitis in children: a review of the benefit/risk ratio of methylprednisolone aceponate.
J Eur Acad Dermatology Venereol, 25 (2011), pp. 508-515
[28]
J.Y. Lee, Y. Her, C.W. Kim, S.S. Kim.
Topical Corticosteroid Phobia among Parents of Children with Atopic Eczema in Korea.
Ann Dermatol, 27 (2015), pp. 499-506
[29]
B. Bos, I. Antonescu, H. Osinga, S. Veenje, K. Jong, T.W. Vries.
Corticosteroid phobia (corticophobia) in parents of young children with atopic dermatitis and their health care providers.
Pediatr Dermatol, 36 (2019), pp. 100-104
[30]
R. Espanha, P. Ávila, R.V. Mendes.
Literacia em Saúde em Portugal: relatório síntese.
[31]
L. Lambrechts, L. Gilissen, M. Morren.
Topical Corticosteroid Phobia Among Healthcare Professionals Using the TOPICOP Score.
Acta Derm Venereol, 99 (2019), pp. 1004-1008
[32]
E.S. Koster, D. Philbert, X. Zheng, N. Moradi, T.W. Vries, M.L. Bouvy.
Reducing corticosteroid phobia in pharmacy staff and parents of children with atopic dermatitis.
Int J Clin Pharm, 43 (2021), pp. 1237-1244

Study conducted at the Department of Dermatology, Centro Hospitalar de Leiria, Leiria, Portugal.

Copyright © 2022. Sociedade Brasileira de Dermatologia
Idiomas
Anais Brasileiros de Dermatologia

Subscribe to our newsletter

Article options
Tools
en pt
Cookies policy Política de cookies
To improve our services and products, we use "cookies" (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here. Utilizamos cookies próprios e de terceiros para melhorar nossos serviços e mostrar publicidade relacionada às suas preferências, analisando seus hábitos de navegação. Se continuar a navegar, consideramos que aceita o seu uso. Você pode alterar a configuração ou obter mais informações aqui.